CHRS - Coherus Biosciences Inc
(NaN%)
Sell
Weak Growth
30%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 33.62%
Operating Income Growth is 45.05%
Net Income Growth is 47.21%
Earnings Per Share (EPS) Growth is 31.71%
Net Margin is 27.79%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.27
Debt Ratio is 0.67
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations Growth is 443.63%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Coherus Biosciences Inc (CHRS) - https://www.coherus.com/
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Dennis Lanfear
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.